Literature DB >> 16303223

Acute effects of tianeptine on circulating neurotransmitters and cardiovascular parameters.

Fuad Lechin1, Bertha van der Dijs, Gerardo Hernández, Beatriz Orozco, Simon Rodríguez, Scarlet Baez.   

Abstract

Tianeptine is a serotonin-uptake enhancer drug whose antidepressant effectiveness is based on its ability to reduce rather than increase serotonin availability at the synaptic cleft. This paradoxical neuropharmacological mechanism has raised doubt among neuropharmacologists and psychiatrists as to the role of tianeptine as a trusty-reliable antidepressant drug. This controversial issue led us to investigate the acute effects of a single, oral dose (12.5 mg) of this drug on circulating neurotransmitters and cardiovascular parameters in 50 healthy subjects. The drug provoked a striking and significant reduction of plasma noradrenaline (NA) and plasma serotonin (f-5-HT) while it increased plasma dopamine (DA) and platelet serotonin (p-5-HT) concentrations within the 4-h study period. No adrenaline (Ad) changes were registered. The NA/Ad ratio and the f-5-HT/p-5-HT ratio showed significant reduction throughout the test. Finally, although diastolic blood pressure (DBP) showed significant decrease, neither systolic blood pressure (SBP) nor heart rate (HR) showed significant change. These findings are consistent with the postulation that tianeptine reduces both neural sympathetic activity and parasympathetic activity without affecting adrenal sympathetic activity, enabling us to discuss the possible mechanisms involved in the antidepressant effects of tianeptine. The well-known fact that major depressed patients always show raised NA plus lower than normal p-5-HT levels, both disorders which are normalized by tianeptine, gives neurochemical support to the clinical improvement triggered by the drug in these patients. Summarizing, the results presented in this study demonstrate that tianeptine triggers significant reduction of circulating noradrenaline and plasma serotonin while increasing circulating dopamine and platelet serotonin. Other possible neuropharmacological effects are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303223     DOI: 10.1016/j.pnpbp.2005.10.013

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Central nervous system plus autonomic nervous system disorders responsible for gastrointestinal and pancreatobiliary diseases.

Authors:  Fuad Lechin; Bertha van der Dijs
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

2.  Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells.

Authors:  Vishruti Makani; James Hall; Khola Qamar; Priyanka Jain; Yonggil Jang; Kenneth Hensley; Joshua J Park
Journal:  Mol Cell Endocrinol       Date:  2013-08-07       Impact factor: 4.102

3.  Differential postpartum sensitivity to the anxiety-modulating effects of offspring contact is associated with innate anxiety and brainstem levels of dopamine beta-hydroxylase in female laboratory rats.

Authors:  C M Ragan; J S Lonstein
Journal:  Neuroscience       Date:  2013-10-22       Impact factor: 3.590

4.  Anorexia nervosa depends on adrenal sympathetic hyperactivity: opposite neuroautonomic profile of hyperinsulinism syndrome.

Authors:  Fuad Lechin; Bertha van der Dijs; Betty Pardey-Maldonado; Jairo E Rivera; Scarlet Baez; Marcel E Lechin
Journal:  Diabetes Metab Syndr Obes       Date:  2010-09-09       Impact factor: 3.168

5.  Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine.

Authors:  Robert H Wichers; James L Findon; Auke Jelsma; Vincent Giampietro; Vladimira Stoencheva; Dene M Robertson; Clodagh M Murphy; Sarah Blainey; Grainne McAlonan; Christine Ecker; Katya Rubia; Declan G M Murphy; Eileen M Daly
Journal:  Mol Autism       Date:  2021-02-19       Impact factor: 7.509

6.  Tianeptine, but not fluoxetine, decreases avoidant behavior in a mouse model of early developmental exposure to fluoxetine.

Authors:  Elizabeth A Pekarskaya; Emma S Holt; Jay A Gingrich; Mark S Ansorge; Jonathan A Javitch; Sarah E Canetta
Journal:  Sci Rep       Date:  2021-11-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.